Ceronapril

Ceronapril
Clinical data
AHFS/Drugs.com	Monograph
ATC code	C09AA09 ( WHO );
Identifiers
	IUPAC name 1-[(2S)-6-Amino-2-hydroxyhexanoyl]-L-proline, hydrogen (4-phenyl-butyl)phosphonate;
CAS Number	111223-26-8 ;
PubChem CID	189729 ;
ChemSpider	164789 ;
UNII	X3MM60SOVP ;
KEGG	D03440 ;
CompTox Dashboard (EPA)	DTXSID80891418 ;
Chemical and physical data
Formula	C30H46NO7P
Molar mass	563.672 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1C[C@H](N(C1)C(=O)[C@H](CCCCN)OP(=O)(CCCCC2=CC=CC=C2)O)C(=O)O;
	InChI InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39-/m1/s1 ; Key:BIDNLKIUORFRQP-YYTCENNOSA-N ;

Last updated December 30, 2025

Ceronapril (INN,^[1] proposed trade names Ceranapril, Novopril) is a phosphonate ACE inhibitor ^[2] that was never marketed.^{[ citation needed ]}

References

↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 31" (PDF). World Health Organization. p. 4. Retrieved 2 March 2017.
↑ Tu JI, Brennan J, Stouffer B, Mantha S, Turabi N, Tsay HM (June 1992). "Radioimmunoassay for ceronapril, a new angiotensin-converting enzyme inhibitor, and its application to a pharmacokinetic study in healthy male volunteers". Therapeutic Drug Monitoring. 14 (3): 209–19. doi:10.1097/00007691-199206000-00007. PMID 1412607. S2CID 23854785.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

This stereochemistry article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[INN-1] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 31" (PDF). World Health Organization. p. 4. Retrieved 2 March 2017.

[2] Tu JI, Brennan J, Stouffer B, Mantha S, Turabi N, Tsay HM (June 1992). "Radioimmunoassay for ceronapril, a new angiotensin-converting enzyme inhibitor, and its application to a pharmacokinetic study in healthy male volunteers". Therapeutic Drug Monitoring. 14 (3): 209–19. doi:10.1097/00007691-199206000-00007. PMID 1412607. S2CID 23854785.

[1]

[2]

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril (+nebivolol) Dicarboxylate-containing: Enalapril ^# (+lercanidipine, +nitrendipine) Benazepril (+amlodipine, +pimobendan) Cilazapril Delapril (+manidipine) Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide) Quinapril (+HCT) Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine) Spirapril Temocapril Trandolapril (+verapamil) Phosphonate-containing : Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan (+amlodipine, +amlodipine and HCT) Eprosartan Fimasartan Irbesartan (+amlodipine, +amlodipine and HCT, +HCT) Losartan (+amlodipine, +HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan ^§ Telmisartan (+amlodipine, +amlodipine and HCT, +amlodipine and indapamide, +HCT) Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren ^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
Other	Sparsentan
^# WHO-EM ^‡ Withdrawn from market Clinical trials: ^† Phase III ^§Never to phase III